FPR1 and breast cancer: Implicit in the disconnection between the two observations (treatment of BV-2 microglial cells with ΔANXA1 4T1 CM versus 4T1 CM with FPRs antagonists) is the interpretation that FPR1/2 was still activated despite genomic deletion of ANXA1 in 4T1 metastatic mammary cancer cells.